

REDX PHARMA PLC
("Redx" or "the Company")

RXC004 Phase 1 monotherapy data to be presented at ESMO Congress 2021

Alderley Park, 13 September 2021, Redx Pharma plc (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces that data from the Company's RXC004 Phase 1 monotherapy study will be presented at the forthcoming European Society for Medical Oncology (ESMO) Congress, 16-21 September 2021.

RXC004 is the Company's lead drug candidate and is a potent, orally active porcupine inhibitor being developed as a targeted therapy for Wnt-ligand driven cancer. Based on the safety profile observed in the Phase 1 study, Redx has selected the 2mg dose of RXC004 for its planned Phase 2 monotherapy, proof of concept clinical trials which are expected to start during the second half of 2021.

The presentation at the ESMO Congress 2021 will be made by the Study Principal Investigator, Dr Natalie Cook, Consultant Medical Oncologist at the Christie Hospital NHS Trust, Manchester, UK.

Presentation No:	517MO
Authors:	N Cook, S Blagden, J Lopez, D Sarker, A Greystoke, N Harris, F Kasmi, A Naderi, G Nintos, A Ortego Franco, R Pihlak, R Shinde, L Goodwin, C Phillips, J Robertson, A Saunders, C Tilston, S Woodcock, R Plummer
Title:	Phase 1 study of the Porcupine (PORCN) inhibitor RXC004 in patients with advanced solid tumours
Day/Date:	Monday 20 September 2021
Presentation Time:	17:50pm to 17:55pm (CET)
Session Channel:	Channel 3
Session Title:	Developmental therapeutics
Session Type:	Mini oral session
Session Time:	17:30pm to 18:30pm (CET)

Redx to host R&D Event

Presented data will be discussed by Medical Experts during Redx's online R&D Event to be held on Monday 11 October 2021 at 1:00pm BST / 8.00am EDT. The event will also cover the Company's pipeline beyond RXC004.

To register for the event, please email redxpharma@fticonsulting.com.

For further information, please contact:

Redx Pharma Plc

UK Headquarters

T: +44 1625 469 918

Lisa Anson, Chief Executive Officer

Karl Hård, Head of Investor Relations

US Office

Peter Collum, Chief Financial Officer

SPARK Advisory Partners (Nominated Adviser)

T: +44 203 368 3550

Matt Davis/Adam Dawes

WG Partners LLP (Joint Broker)

T: +44 20 3705 9330

Claes Spång/Nigel Birks/David Wilson

Panmure Gordon (UK) Limited (Joint Broker)

T: +44 20 7886 2500

Rupert Dearden/Freddy Crossley/Emma Earl

FTI Consulting

T: +44 20 3727 1000

Simon Conway/Ciara Martin

About Redx Pharma Plc

Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic diseases, aiming initially to progress them to clinical proof of concept, before evaluating options for further development and potential value creation. Redx's lead oncology asset, RXC004, is currently in a Phase 1 study in patients with advanced malignancies and intends to initiate multiple Phase 2 studies in H2 2021. The Company's selective ROCK2 inhibitor, RXC007, is in development for idiopathic pulmonary fibrosis and recently commenced a Phase 1 clinical study in June 2021 where headline results are expected in H1 2022.

The Company has a strong track record of discovering new drug candidates through its core capability of converting medicinal chemistry insights into differentiated and commercially attractive drug candidates, and has previously completed preclinical asset transactions with Loxo Oncology (now Eli Lilly), AstraZeneca and Jazz Pharmaceuticals.

To subscribe to RNS announcements from Redx, please visit:
<https://www.redxpharma.com/investor-centre/email-alerts>